# Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer

> **NCT06284746** · PHASE2 · UNKNOWN · sponsor: **Lin Chen** · enrollment: 80 (estimated)

## Conditions studied

- Locally Advanced Gastric Carcinoma
- HER2 Negative
- Efficacy
- Safety

## Interventions

- **DRUG:** Tirolizumab+SOX/XELOX
- **DRUG:** SOX/XELOX

## Key facts

- **NCT ID:** NCT06284746
- **Lead sponsor:** Lin Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-01
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06284746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06284746, "Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06284746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*